dapolsertib (MEN1703)

News alerts, weekly reports and conference planners

Company:

Menarini, Ryvu Therap

Drug class:

FLT3 inhibitor, PIM inhibitor

Related drugs:

›

IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C3 – Early Trials MEN1703 Sensitive : C3	MEN1703 Sensitive: C3 – Early Trials MEN1703 Sensitive : C3

Associations
(2)